References
- Jao GT, Chiong JR. Hyponatraemia in acute decompensated heart failure: mechanisms, prognosis, and treatment options. Clinical cardiology. 2010 Nov;33(11):666-71.
- Ede KÉ, István BA, Tenno DA, Gergely DA, István KI. A hyponatraemia diagnosztikájának és kezelésének gyakorlati útmutatója. Elérhető: https://www.doki.net/tarsasag/nephrologia/upload/nephrologia/document/HN_2015_3_iranyelv_kommentar.pdf?web_id=
- la Nuez Veulens A, Ginarte YM, Fernandez RE, Leclerc F, Cabrera LA. Prediction of molecular interactions and physicochemical properties relevant for vasopressin V2 receptor antagonism. Journal of Molecular Modeling. 2022 Feb; 28(2):31.
- Rondon-Berrios H, Berl T. Vasopressin receptor antagonists in hyponatraemia: uses and misuses. Frontiers in medicine. 2017 Aug 21;4:141.
- Jao GT, Chiong JR. Hyponatraemia in acute decompensated heart failure: mechanisms, prognosis, and treatment options. Clinical cardiology. 2010 Nov;33(11):666-71.
- Vígh J, Ábrahám G, Kálmán J, Zöllei M, Forster T. A hyponatraemia klinikai jelentősége. Orvosi Hetilap. 2019 Feb;160(8):314-9.
- Gyires K, Fürst Zs, Ferdinandy P – Farmakológia és klinikai farmakológia, Medicina, Budapest, 2020, 261-277.
- https://www.pharmindex-online.hu/uj-gyogyszercsoport-elso-tagja-tolvaptan
- G. Aperis, P. Alivanis – Tolvaptan: A New Therapeutic Agent, Recent Clinical Trials, 2011, 6(2).
- J.G. Verbalis – AVP Receptor Antagonists as Aquaretics: Review and Assessment of Clinical Data, Cleveland Clinic Journal of Medicine, 2006, 73(3).
- C. Villabona – Antagonistas del receptor de vasopresina: Los vaptanes, Endocrinologia y Nutricion, 2010, 57(2): 41–52.
- T. Titko, L. Perekhoda, I. Drapak, Y. Tsapko – Modern trends in diuretics development, European Journal of Medicinal Chemistry, 2020, 208.
- https://www.ema.europa.eu/en
- https://www.otsuka.co.jp/en/company/newsreleases/2018/20180425_1.html
- https://www.ema.europa.eu/en/medicines/human/EPAR/samsca
- https://investors.centessa.com/news-releases/news-release-details/centessa-pharmaceuticals-makes-strategic-decision-discontinue
- https://www.pharmaceutical-technology.com/data-insights/balovaptan-f-hoffmann-la-roche-post-traumatic-stress-disorder-ptsd-likelihood-of-approval/?cf-view
- Liu C, Xia L, Fu K, Cao X, Yan W, Cheng J, Roux T, Peletier LA, Yin X, Guo D. Revisit ligand-receptor interaction at the human vasopressin V2 receptor: A kinetic perspective. European Journal of Pharmacology. 2020 Aug 5;880:173157.
- https://pubchem.ncbi.nlm.nih.gov/
- https://patents.google.com/patent/CN102060769B/en
- https://go.drugbank.com/drugs/DB00872
- https://go.drugbank.com/drugs/DB06212
- https://go.drugbank.com/drugs/DB06666
- https://go.drugbank.com/drugs/DB13929
- https://go.drugbank.com/drugs/DB14823
- Patil MR, Patil AS, Shirkhedkar AA. Novel and ecofriendly UV-Spectrophotometry methods for estimation of Tolvaptan using hydrotropic agent. International Journal of Pharmaceutical Chemistry. 2020;6:115-9.
- Jiang J, Tian L, Huang Y, Yan Y, Li Y. A rapid and sensitive LC–MS/MS-ESI method for the determination of tolvaptan and its two main metabolites in human plasma. Journal of Chromatography B. 2016 Aug 1;1027:158-64.
- Sebaiy MM, Sm EA, Mm B, Aa H. Analytical Methods for Determination of Certain Sartans and Diuretics. J. Chem. Sci. Chem. Eng. 2020;1:11-8.
- Q. Pei et al. – Development and validation of an LC-MS/MS method for the determination of tolvaptan in human plasma and its application to a pharmacokinetic study, J Chromatogr B Analyt Technol Biomed Life Sci, 2013, 913–914: 84–89.
- P. Guo et al. – Simultaneous determination of canrenone, digoxin and tolvaptan by UHPLC-MS/MS: Application in heart failure patients, Bioanalysis, 2020, 12(9): 569–582.
- Furukawa M, Yamasaki Y, Hirao Y, Umehara K. Enantioselective analysis of tolvaptan in rat and dog sera by high-performance liquid chromatography and application to pharmacokinetic study. Journal of Chromatography B. 2014 Aug 15;965:112-8.
- S. Akutsu, T. Naito, K. Hoshikawa, M. Saotome, Y. Maekawa, J. Kawakami – An enantiomeric quantitative LC-MS/MS method for tolvaptan and its monohydroxylates in human plasma using a reversed-phase separation procedure, J Pharm Biomed Anal, 2020, 180.
- Mazzarino, M., Buccilli, V., De la Torre, X., Fiacco, I., Palermo, A., Ughi, D. and Botrè, F., 2017. Characterization of the phase I and phase II metabolic profile of tolvaptan by in vitro studies and liquid chromatography–mass spectrometry profiling: Relevance to doping control analysis. Journal of Pharmaceutical and Biomedical Analysis, 145, pp.555-568.
- Gaibelet G, Fouillen A, Stéphanie R, Orcel H, Mendre C, Kanso A, Lanotte R, Nguyen J, Dimon J, Urbach S, Sounier R. Biased activation of the vasopressin V2 receptor probed by NMR, paramagnetic ligands, and molecular dynamics simulations. bioRxiv. 2023:2023-06.
- Kadi AA, Alrabiah H, Attwa MW, Attia S, Mostafa GA. Development and validation of HPLC‐MS/MS method for the determination of lixivaptan in mouse plasma and its application in a pharmacokinetic study. Biomedical Chromatography. 2017 Nov;31(11):e4007.
- AlRabiah H, Bakheit A, Abounassif M, Mostafa GA. Spectrofluorimetric methods for the determination of lixivaptan and its hydrolysis product in human plasma and urine, with factors optimization study. Journal of Molecular Liquids. 2018 Jan 1;249:764-71.
- Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T. Tolvaptan, an Orally Active Vasopressin V2‐ Receptor Antagonist—Pharmacology and Clinical Trials. Cardiovascular drug reviews. 2007 Mar;25(1):1-3.Decaux G. V2-antagonists for the treatment of hyponatraemia. Nephrology Dialysis Transplantation. 2007 Jul 1;22(7):1853-5.
- Lava SA, Zollinger C, Chehade H, Schaffner D, Sekarski N, Di Bernardo S. Diuretics in pediatrics. European Journal of Pediatrics. 2023 May;182(5):2077-88.
- Kondo K, Yamamura Y. The Discovery of Samsca®(Tolvaptan): The First Oral Nonpeptide Vasopressin Receptor Antagonist. Case Studies in Modern Drug Discovery and Development. 2012 May 11:336-59.
- J.J. Liu, D.S. Johnson – Modern Drug Sythesis, John Willey and son, New Jersey, 2010, 175-189.
- https://www.chemicalbook.com/ (Utolsó megnyitás dátuma 2023.05.10)
- Matsuura R, Doi K. Vaptans and the Treatment of Hyponatraemia. InCritical Care Nephrology 2019 Jan 1 (pp. 364-368). Elsevier.
- Rangarajan B, Binoy V, Hingmire SS, Noronha V. Tolvaptan. South Asian journal of cancer. 2014 Jul;3(03):182-4.
- Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. The Lancet. 2008 May 10;371(9624):1624-32.
- Tzoulis P, Kaltsas G, Baldeweg SE, Bouloux PM, Grossman AB. Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD). Therapeutic Advances in Endocrinology and Metabolism. 2023 May;14:20420188231173327.
- https://ichgcp.net/hu/clinical-trials-registry/NCT04782258
- Der‐Nigoghossian C, Lesch C, Berger K. Effectiveness and tolerability of conivaptan and tolvaptan for the treatment of hyponatraemia in neurocritically ill patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2017 May;37(5):528-34.
- Heidman LM, Peinetti N, Copello VA, Burnstein KL. Exploiting dependence of castration-resistant prostate cancer on the arginine vasopressin signaling axis by repurposing vaptans. Molecular Cancer Research. 2022 Aug 5;20(8):1295-304.
- Marroncini G, Anceschi C, Naldi L, Fibbi B, Baldanzi F, Martinelli S, Polvani S, Maggi M, Peri A. Low sodium and tolvaptan have opposite effects in human small cell lung cancer cells. Molecular and Cellular Endocrinology. 2021 Nov 1;537:111419.
- Sinha S, Dwivedi N, Tao S, Jamadar A, Kakade VR, Neil MO, Weiss RH, Enders J, Calvet JP, Thomas SM, Rao R. Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. Oncogene. 2020 Feb 6;39(6):1231-45.
- Silva DL, Damasceno LL, Sales EF. Balovaptan and Autism Spectrum Disorder. Insights Biomed Res. 2020;4(1):120-4.
- Schnider P, Bissantz C, Bruns A, Dolente C, Goetschi E, Jakob-Roetne R, Künnecke B, Mueggler T, Muster W, Parrott N, Pinard E. Discovery of balovaptan, a vasopressin 1a receptor antagonist for the treatment of autism spectrum disorder. Journal of medicinal chemistry. 2020 Jan 17;63(4):1511-25.
- Hollander E, Jacob S, Jou R, McNamara N, Sikich L, Tobe R, Smith J, Sanders K, Squassante L, Murtagh L, Gleissl T. Balovaptan vs placebo for social communication in childhood autism spectrum disorder: a randomized clinical trial. JAMA psychiatry. 2022 Aug 1;79(8):760-9.
- Jacob S, Veenstra-VanderWeele J, Murphy D, McCracken J, Smith J, Sanders K, Meyenberg C, Wiese T, Deol-Bhullar G, Wandel C, Ashford E. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. The Lancet Psychiatry. 2022 Mar 1;9(3):199-210.
- Kimi S, Maiti R, Srinivasan A, Mishra BR, Hota D. Efficacy and safety of V1a receptor antagonists in autism spectrum disorder: A meta‐analysis. International Journal of Developmental Neuroscience. 2024 Feb;84(1):3-13.
- Baska F, Bozó É, Patócs T. Vasopressin receptor antagonists: a patent summary (2018-2022). Expert Opinion on Therapeutic Patents. 2023 May 4(just-accepted).
- Brouard R. Relcovaptan for the prevention of dysmenorrhoea?. Inpharma. 2000 Jun;1240:3.
- Izumi Y, Miura K, Iwao H. Therapeutic potential of vasopressin-receptor antagonists in heart failure. Journal of pharmacological sciences. 2014 Jan 1;124(1):1-6.
- Sandgren JA, Linggonegoro DW, Pearson NA, Perschbacher KJ, Santillan DA, Scroggins SM, Gibson‐Corley KN, Pierce GL, Santillan MK, Grobe JL. Vasopressin Induces Discrete Symptoms of Preeclampsia through Receptor‐and Gestational Age‐Specific Mechanisms. The FASEB Journal. 2017 Apr;31:1027-6.
- Ali F, Raufi MA, Washington B, Ghali JK. Conivaptan: a dual receptor vasopressin v1a/v2 antagonist. Cardiovascular drug reviews. 2007 Sep;25(3):261-79.
- Zinkovsky D. Side effects, ADRs & ADEs of diuretics. InSide Effects of Drugs Annual 2021 Jan 1 (Vol. 43, pp. 259-265). Elsevier.
- Lehrich RW, Ortiz-Melo DI, Patel MB, Greenberg A. Role of vaptans in the management of hyponatraemia. American journal of kidney diseases. 2013 Aug 1;62(2):364-76.
- Hirai T, Kondo Y, Sakazaki Y, Seki A, Ishitsuka Y, Iwamoto T. Drug–drug interaction signals between loop diuretics and teicoplanin during acute kidney injury evaluated using Japanese spontaneous adverse drug event reports. Scientific Reports. 2023 Aug 26;13(1):13989.
- Bhave N, Gluckman T, Wiggins B. Drug-drug interactions with Paxlovid and select cardiovascular medications. Elérhető:
- https://deepblue.lib.umich.edu/bitstream/handle/2027.42/174744/COVID-Drug-Clinical-Bulletin.pdf?sequence=2
- Shoaf SE, Bricmont P, Mallikaarjun S. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non‐peptide AVP antagonist in healthy subjects. British journal of clinical pharmacology. 2012 Apr;73(4):579-87.
- Hellenbart EL, Kaluzna SD, DiDomenico RJ. Principles of Heart Failure Pharmacotherapy. Heart Failure. 2022 Jul 11:41-55.
- https://ec.europa.eu/health/documents/community-register/2017/20170918138728/anx_138728_hu.pdf
- Cresswell FV, Musubire AK, Århem KM. Treatment guidelines for tuberculosis and tuberculous meningitis. InTuberculous Meningitis 2020 Jan 1 (pp. 67-101). Academic Press.